januari 26, 2022

Ectin Research AB appoints Dr Austin Smith as new Chief Medical Officer

Stockholm, Sweden, January 26, 2022,  Ectin Research has appointed Dr. Austin Smith as the company’s Chief Medical Officer (CMO). Dr. Smith specializes in medical oncology with a special interest and extensive experience in clinical drug development. Dr. Smith is replacing Dr. Steven Glazer, who is leaving his position in the Company to focus on other commitments.

Dr. Austin Smith has been recruited as Ectin Research’s new CMO. Dr Austin Smith is a medical graduate of the Royal College of Surgeons, Ireland. He has a special interest in clinical drug development and has held a wide range of senior clinical and strategic positions within oncology. He is currently ”Principal Medical Consultant” at Scendea Ltd, a consulting company focusing on product development and regulatory activities in the pharmaceutical and biotech industries. In parallel, he also runs SwiftBio Consulting Ltd, a company that supports the pharmaceutical industry in clinical development activities as ”Medical Director”. Prior to that, he was employed by the contract research organization (CRO): LINK Medical Research AS as ”Vice President Clinical Development” and Theradex Oncology Ltd as ”Medical Director”.

Ectin Research’s CEO Anna Sjöblom-Hallén: “We are extremely pleased to recruit Dr Austin Smith, a very senior oncologist with solid expertise in clinical drug development. Dr. Smith is well acquainted with Ectin Research and our project from his time at LINK Medical Research when he acted as senior advisor to us. We now wish Dr. Steven Glazer, who has been with us for many years and contributed well in preparing the activities for our clinical phase I / II study, our best wishes for the future.”